Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Israeli archaeologists launch project to trace origins of ancient pottery - 2Pick Your #1 Japanese Food
- 3The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- 4ByHeart sued over recalled formula by parents of infants sickened with botulism
- 5I'm an 83-year-old yoga instructor. I'm not your typical grandma — I still work to feel fulfilled and supplement my Social Security.
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Must-See Attractions in Australia
- A Manual for Extravagant Vehicles Available in 2024
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- 7 Moves toward a Sound and Dynamic Way of life
- Europe pledges over €15bn for clean energy for Africa
